Eli Lilly’s weight loss drug slashes the risk of developing diabetes in long-term trial
The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period. Source
Read MoreThe late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period. Source
Read MoreDrugstores remain an important fixture of the U.S. health-care system that tens of millions of Americans rely on, but they
Read MoreBayer shares rose as the company said it scored a legal victory in its suit over claims that exposure to
Read MoreThe Medicare negotiations are a multi-round process that could produce more savings for taxpayers and seniors and put more pressure
Read MoreIt is a milestone in a controversial process that aims to make costly medications more affordable for older Americans but
Read MoreRo said it hopes its new tool will be able to help patients understand their GLP-1 coverage options so they
Read MoreThese dividend stocks are poised to move higher after the Federal Reserve starts cutting rates, says BMO. Source link
Read MoreModerna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance
Read MoreThe study results on Leqembi, which Eisai shares with Biogen, also found that Alzheimer's patients who take the therapy get
Read More